Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Neuropsychopharmacology. 2011 Feb 16;36(6):1260–1274. doi: 10.1038/npp.2011.12

Figure 8.

Figure 8

LY379268 also recovered the acute MK-801 effects on the expressions of both NR2A subunit and Akt/GSK-3β activity at medium dose. (A) Medium dose of MK-801 (0.1 mg/kg, single dose) induced significant increase of NR2A (P <0.05), but not NR2B subunit and intermediate dose of LY379268 (1.0 mg/kg) recovered the NR2A expression without a clear effect on NR2B. (B) Medium dose of MK-801 induced significant decreases of both pGSK/GSK and pAkt/Akt ratios (P <0.05) but had no clear effects on the total protein levels of GSK-3β and Akt. Medium dose of LY379268 reversed the pGSK/GSK and pAkt/Akt ratios and exhibited no effects on the total protein expressions of GSK-3β and Akt.